NCT01239134 - Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

Interventions

BIOLOGICAL

TRX518

Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody

Trial Locations (1)

Immunotherapeutics Core / Memorial Sloan Kettering Cancer Center, New York